• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Akorn agrees to manufacture, supply ophthalmic solution

Article

Buffalo Grove, IL-Akorn has signed a 5-year contract with a major U.S. pharmaceutical company to manufacture and supply an ophthalmic drug product in Akorn’s Somerset, NJ, facility, the company has announced.

Buffalo Grove, IL-Akorn has signed a 5-year contract with a major U.S. pharmaceutical company to manufacture and supply an ophthalmic drug product in Akorn’s Somerset, NJ, facility, the company has announced.

Akorn holds the abbreviated new drug application for the product and also expects to launch it under the Akorn label in mid-2008. The current market size for the drug is about $25 million, according to Akorn, citing recent IMS sales data.

“We are very pleased to have been selected as the contract manufacturer for this important ophthalmic product,” said Arthur S. Przybyl, Akorn’s president and chief executive officer. “We continue to seek contract pharmaceutical manufacturing opportunities in ophthalmics, liquid injectables, and lyophilized products in order to expand these businesses.”

Related Videos
Video 2 - 1 KOL is featured in, "Advances in Technology for SMILE procedure"
Video 1 - 1 KOL is featured in, "Overview of Small Incision Lenticule Extraction (SMILE)"
Vicki Chan, MD, shares pearls for leveraging the power of social media in health care
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.